MRG-001
Phase 2Small molecule
MRG-001 is one of 74 small molecule programs targeting ARDS. It is currently in Phase 2.
3
Indications
5
Total Trials
3
Active Trials
73
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
55 competitors in Amyotrophic Lateral Sclerosis
#DrugCompanyPhaseTrials
1Enablex
AbbVieApproved
Vimpat
UCBApproved
Nourianz
Kyowa Kirin Co., Ltd.Approved
Bosulif
PPrism Pharmaceuticals
Approved
Qalsody
BiogenApproved
Rapamune
PPrism Pharmaceuticals
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Mirapex
Boehringer IngelheimApproved
Atropen
FFresenius Kabi Taiwan Ltd.
Approved
Transderm Scop
BBaxter Healthcare Corporation
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MRG-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMedRegen LLC